Table 4.
Summary of studies reporting relationships between dosimetric parameters and radiation pneumonitis (RP) after thoracic radiotherapy.
| References | N | Tumor | Prescribed dose (Gy) | Chemotherapy (%) | RP (%) | MLD (Gy) | Lung V20 (%) | MHD (Gy) |
|---|---|---|---|---|---|---|---|---|
| This study | 70 | TET | 58.3 | 49 | 19 | 9.7 | 16.6 | 14.9 |
| 1a | 151 | LANSCLC | 60 | 100 | 8.6 | 16.5 | 29.0 | NA |
| 11 | 209 | LANSCLC | 50–84 | 55 | 23 | 18.2 | NA | 13.9 |
| 13 | 71 | LANSCLC | 60 | 100 | 28.2 | NA | 23.0 | NA |
| 14 | 836 | LANSCLC | 60 | 100 | 29.8 | 17 | 30 | NA |
| 19 | 125 | Esophagus ca | 60 | 100 | 20.8 | 9.5 | 18.2 | NA |
| 20 | 37 | Esophagus ca | 60 | 100 | 35.1 | 16.6 | 34.8 | NA |
| 21 | 629 | LANSCLC | 63 | 100 | 42 | 20.1 | 23.0 | 19.2 |
| 22 | 176 | LANSCLC | 60–65 | 71 | 39 | 14.4–19.4 | NA | 16.0–21.3 |
Data were described as equivalent 2-Gy fractions (EQD2) using the LQ model with α/β = 3 Gy.
MLD mean lung dose, V20 percentage volume receiving at least 20 Gy, MHD mean heart dose, TET thymic epithelial tumors, LANSCLC locally advanced non-small-cell lung cancer, NA not applicable, Esophagus ca esophagus cancer.
aData of the 60 Gy without cetuximab group.